Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC

Pfizer’s prostate cancer therapy Talzenna, when combined with Xtandi, can extend overall survival (OS) by nearly nine months over the standard of care (SoC), according to a Phase III trial.